For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
This week in health care policy: October 31-November 6, 2026
Drug pricing and PBMs Medicare’s second round of negotiated prices starts in two months. On January 1, negotiated prices for…
Blog
This week in health care policy: October 24-30, 2026
FDA and innovation FDA and CMS move on personalized gene therapies. The FDA released draft guidance that lets developers of…
Blog
Market-oriented reforms that can save Medicare $100 billion
Since 1970, Medicare spending has grown from 0.7 percent of GDP to 4.0 percent of GDP, and it is projected to grow even further.
Search Posts
News Release
Study Argues for Protection of Incremental Drug Advances
Normal 0 false false false MicrosoftInternetExplorer4 Normal 0 false false false MicrosoftInternetExplorer4 /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-parent:"";…
Blog
Baptist-Bootlegger Alliance on Tobacco
In today’s Washington Examiner, Tim Carney has an excellent column on how the bill to place tobacco under FDA regulation would reduce competition in…
Citation
H.R. 875, Food Safety Modernization Act of 2009
Study
Pharmaceutical Evolution
Albert I. Wertheimer and Thomas M. Santella explain the advantages of incremental innovation in drug development. Photo: CC <a href="http://www.flickr.com/photos/joethorn/86495698/">Joe Thorn</a>.
Newsletter
Cancer Treatment, Global Warming Doublespeak and Counting All the Votes in NY
Shares of Dendreon Corp. rise as analysts look forward to new data on its experimental prostate cancer drug, Provenge. Public relations practitioners complain of scientists…
Newsletter
Cancer Drugs, Voting Rights and Cap and Trade Controversy
Author Virginia Postrel details her successful battle against breast cancer. The Justice Department re-considers whether the proposed D.C. voting rights bill is constitutional. States with…